Salarius Fixed Asset Turnover from 2010 to 2024

SLRX Stock  USD 1.37  0.09  6.16%   
Salarius Pharmaceuticals Fixed Asset Turnover yearly trend continues to be fairly stable with very little volatility. Fixed Asset Turnover is likely to outpace its year average in 2024. During the period from 2010 to 2024, Salarius Pharmaceuticals Fixed Asset Turnover regression line of annual values had r-squared of  0.75 and arithmetic mean of  86.37. View All Fundamentals
 
Fixed Asset Turnover  
First Reported
2010-12-31
Previous Quarter
210.18
Current Value
220.69
Quarterly Volatility
107.85268458
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Salarius Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Salarius Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Income of 441.7 K, Depreciation And Amortization of 9.55 or Interest Expense of 281.6 K, as well as many indicators such as Price To Sales Ratio of 97.37, Dividend Yield of 0.0011 or PTB Ratio of 3.05. Salarius financial statements analysis is a perfect complement when working with Salarius Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Salarius Pharmaceuticals Correlation against competitors.
For more information on how to buy Salarius Stock please use our How to Invest in Salarius Pharmaceuticals guide.

Latest Salarius Pharmaceuticals' Fixed Asset Turnover Growth Pattern

Below is the plot of the Fixed Asset Turnover of Salarius Pharmaceuticals over the last few years. It is Salarius Pharmaceuticals' Fixed Asset Turnover historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Salarius Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Fixed Asset Turnover10 Years Trend
Slightly volatile
   Fixed Asset Turnover   
       Timeline  

Salarius Fixed Asset Turnover Regression Statistics

Arithmetic Mean86.37
Geometric Mean14.38
Coefficient Of Variation124.88
Mean Deviation99.92
Median3.85
Standard Deviation107.85
Sample Variance11,632
Range232
R-Value0.86
Mean Square Error3,162
R-Squared0.75
Significance0.000032
Slope20.85
Total Sum of Squares162,851

Salarius Fixed Asset Turnover History

2024 220.69
2023 210.18
2021 233.53
2020 231.16
2019 138.51
2018 11.32
2017 3.85

About Salarius Pharmaceuticals Financial Statements

Salarius Pharmaceuticals investors use historical fundamental indicators, such as Salarius Pharmaceuticals' Fixed Asset Turnover, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Salarius Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Fixed Asset Turnover 210.18  220.69 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Salarius Stock Analysis

When running Salarius Pharmaceuticals' price analysis, check to measure Salarius Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Salarius Pharmaceuticals is operating at the current time. Most of Salarius Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Salarius Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Salarius Pharmaceuticals' price. Additionally, you may evaluate how the addition of Salarius Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.